Strategic question
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target.
How Galen Growth helped
From market signal to decision-ready evidence
Based on our Similarity Score, proprietary to HealthTech Alpha, we selected 50 ventures across the globe with both full and partial product similarity. Based on the profiling of these ventures, we collaborated with our client to select a priority list of 15 ventures and conducted a full Deep Dive analysis of their products, clinical strength and unique selling proposition to build a comparison matrix to further assess their initial investment target. The examination covered Genomics ventures across the globe. Of all ventures we screened 50 and shortlisted a total of 15 companies for selection.
Outcomes
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Mapping the Real-World Evidence Landscape in China for an Investor Thesis
Is real-world evidence in China a defensible thesis, and which ventures are emerging as category leaders?
Macro and micro-environment analysis in RWD & RWE
The Corporate Venture Capital (CVC) arm of a global pharmaceutical company wanted to analyse a specific key APAC market to assess both the macro and micro-environment for Real World Data and Real Word Evidence to inform corporate strategy and prioritise key ventures for further engagement. By utilising Galen Growth's proven PlayBook methodology, we enabled our client to fully understand the RWD and RWE innovation environment and readiness to enable the identification and prioritisation of Digital Health ventures with the right capabilities and achievements. Further prioritisation driven by Deep Dive analysis of select ventures, to map their operating model, leading to direct engagement with their leadership team. The examination covered 1 key therapeutic area in 1 key APAC country. We screened 15 ventures and, in collaboration with our client, shortlisted 7.
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?